$MODD

Director at Modular Medical (MODD) awarded fully vested options for 250 shares

Modular Medical, Inc. director Philip Brent Sheibley was granted 250 fully vested stock options with an exercise price of $4.55 per share, under the company's Outside Director Compensation Plan. The options are exercisable immediately and expire on March 31, 2036. This transaction was reported in a Form 4 SEC filing by StockTitan.

Original reporting
Published Apr 9, 2026, 4:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 9, 2026, 4:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$MODD
Neutral
medium confidence
Mentioned
$MODD
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$MODDNeutralMed
01

Why it matters

Such insider activities can influence short-term trading behavior, but long-term impact depends on company fundamentals.

02

Market read

The news has moderate relevance for traders interested in MODD, primarily affecting short-term sentiment.

03

What to watch

Market-wide volatility or upcoming earnings reports could overshadow insider activity impact.

Timing: immediate

Background

Modular Medical, Inc. recently filed SEC Form 4 reporting insider stock options grants, indicating ongoing compensation activities.

Company-level read

Ticker impact

$MODDNeutralMedium confidence
Context

The news pertains to insider stock options granted to a director of Modular Medical, Inc., which could influence investor perception and stock price.

Expected impact

Potential slight upward movement in MODD stock price in the short term.

Evidence & confidence

While insider transactions can indicate confidence, the impact depends on overall market conditions and investor interpretation.

Market effects

Possible positive sentiment towards biotech and medical device sectors.

Limited regional impact due to company-specific news.

Minimal global market relevance.

Counterpoint

Insider grants may be routine and not indicative of future performance; stock could remain unchanged or decline.

Key entities

  • Modular Medical, Inc.

    A medical device company focused on innovative solutions.

  • Philip Brent Sheibley

    Director of Modular Medical who received stock options.

Related articles

$SPCXMed

Billionaire Ron Baron makes $24.9 billion bet on controversial giant

Baron Capital's Q2 13F filing reveals a $24.9 billion stake in SpaceX (SPCX), making it 37.38% of its $66.64 billion portfolio. SPCX closed at $136.97, below Baron's average cost of $170.86. SpaceX reported Q2 2026 revenue of $7.8 billion, a 92% YOY increase, and adjusted EBITDA of $3.5 billion, up 191%. Baron's long-term strategy focuses on growth potential, despite short-term volatility and valuation concerns.

$RSGMed

Gates-Backed Cascade Sees Opportunity in Republic Services That Half of Wall Street Misses

Cascade Investment, managing Bill Gates' fortune, disclosed buying 654,430 shares of Republic Services (RSG) over four days at prices between $213.70 and $217.18. Cascade now owns 10% of the waste hauler. Republic's Q2 2026 earnings showed 5.3% core price growth, 32.1% EBITDA margin, and raised full-year guidance. Analysts are split, with a consensus target of $245.92, while the stock closed at $220.67.

$GRMLMed

Greenland Mines Delivers Landmark S-K 1300 Mineral Resource Estimate for Sarfartoq in Greenland; First-Ever Indicated Resource and First Combined Open Pit/Underground Resource for the Critical Nd-Pr M

Greenland Mines Ltd (GRML) announced a landmark S-K 1300 Technical Report for its Sarfartoq Nd-Pr Rare Earths Project in Greenland, prepared by Tetra Tech and GeoSim. The report includes an Indicated Mineral Resource category and a combined open pit/underground resource estimate, marking a first for the project. The resource contains approximately 40,700 tons of neodymium and praseodymium oxide, equivalent to about five years of non-Chinese refined supply in 2025. The company believes Sarfartoq

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$CXTLow

Crane NXT (CXT) Could Be 25% Below Fair Value As New President Takes Key Role

Crane NXT (CXT) appointed Jason Lund as President of Crane Payment Innovations and Group President of its Detection and Traceability Technologies segment. The stock trades at $50.20, with a 90-day return of 23.07% but a 1-year return of -18.55%. Analysts suggest it may be 25% undervalued at $66.83, citing growth potential in authentication and cybersecurity, though digital payment shifts and acquisition risks remain.